20/20 BioLabs reported second quarter 2026 revenue of $0.73 million, a 36.5% increase year-over-year, driven by record multi-cancer early detection (MCED) testing volume. Despite the growth, net loss widened to $1.51 million from $0.84 million in the prior year, largely due to one-time Nasdaq listing costs and increased operating expenses.
Key Highlights
- Gross margin expanded 1,120 basis points to 41.7% from 30.5% as laboratory fixed-cost absorption improved with higher testing volumes.
- OneTest family revenue increased 47.1% year-over-year to $0.70 million, now representing 95.3% of total company revenue.
- The company eliminated all outstanding convertible note debt during the quarter and ended the period with a cash balance of $4.5 million.